Vanda Pharmaceuticals Inc.

VNDA

US9216591084

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 06/03/2026 GMT			5-day change	1st Jan Change
7.890 ^USD	-0.25%		-11.45%	-10.54%

03-05	Truist Initiates Vanda Pharmaceuticals at Buy With $18 Price Target	MT
03-05	Vanda Pharmaceuticals Insider Sold Shares Worth $1,276,971, According to a Recent SEC Filing	MT

Vanda Pharmaceuticals Says FDA Accepts Bysanti Application for Bipolar I, Schizophrenia

Published on 05/05/2025 at 03:49 pm BST

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Vanda Pharmaceuticals Inc.

03-05	Truist Initiates Vanda Pharmaceuticals at Buy With $18 Price Target	MT
03-05	Vanda Pharmaceuticals Insider Sold Shares Worth $1,276,971, According to a Recent SEC Filing	MT
03-03	Vanda Pharmaceuticals Inc. Announces FDA Grants Landmark Hearing for HETLIOZin Jet Lag Disorder	CI
03-03	Vanda announces FDA grants landmark hearing for Hetlioz® in jet lag disorder, the first drug approval hearing in over 40 years	RE
03-03	Vanda Pharmaceuticals Wins Rare FDA Hearing on HETLIOZ Application for Jet Lag	MT
02-27	European Medicines Agency Panel Issues Negative Opinion on Vanda's Schizophrenia Treatment	MT
02-27	Vanda Pharmaceuticals Receives Negative Opinion From European Medicines Agency's CHMP for Iloperidone	MT
02-27	Ema's CHMP recommended granting a marketing authorisation for Mcombriax	RE
02-25	Vanda Pharmaceuticals Says US FDA Accepts Imsidolimab BLA for Rare Skin Disease	MT
02-25	B. Riley Adjusts Vanda Pharmaceuticals Price Target to $17 From $14, Maintains Buy Rating	MT
02-25	Vanda Pharmaceuticals Announces Fda Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis	CI
02-25	Vanda Pharmaceuticals announces FDA acceptance of Biologics License Application filing for Imsidolimab for the treatment of generalized pustular psoriasis	RE
02-23	Top Premarket Gainers	MT
02-23	Vanda Pharmaceuticals Gain Following FDA Approval of Bipolar, Schizophrenia Treatment	DJ
02-23	Vanda Gets FDA Approval for Bysanti in Schizophrenia, Bipolar I Disorder; Shares Up Pre-Bell	MT

Chart Vanda Pharmaceuticals Inc.

Duration

Period

VNDA: Dynamic Chart

Vanda Pharmaceuticals Inc. is a biopharmaceutical company, which is focused on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The Companyâ€™s commercial portfolio is comprised of three products: HETLIOZ for the treatment of non-24-hour sleep-wake disorder (Non-24) and for the treatment of nighttime sleep disturbances in smith-magenis syndrome (SMS), Fanapt (iloperidone) for the treatment of bipolar I disorder and a long acting injectable (LAI) formulation for the treatment of schizophrenia, and PONVORY (ponesimod) for the treatment of inflammatory/autoimmune disorders, including ulcerative colitis, psoriasis, Crohn's disease, atopic dermatitis, eosinophilic esophagitis and alopecia areata. The Company also has a range of drugs in development, including Tradipitant (VLY-686), VHX-896, VSJ-110, VPO-227, VTR-297, VQW-765, VCA-894A and Type 2S (CMT2S).

Employees

533

Sector

Biotechnology & Medical Research

More about the company